AGIO— AGIOS PHARMACEUTICALS, INC.

MaterialsBiotechnology$2.0B mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Total product revenue, net	$54.0M+48.0%	$36.5M+36.1%	$26.8M+88.4%	$14.2M
Cost of sales	$6.3M+52.3%	$4.2M+44.6%	$2.9M+69.1%	$1.7M
Research and development	$339.5M+12.7%	$301.3M+1.9%	$295.5M+5.6%	$279.9M
Total selling, general and administrative expenses	$180.3M+15.0%	$156.8M+30.8%	$119.9M-1.5%	$121.7M
Total operating expenses	$526.2M+13.8%	$462.2M+10.5%	$418.3M+3.7%	$403.3M
Loss from operations	-$472.1M-10.9%	-$425.7M-8.7%	-$391.5M-0.6%	-$389.0M
Gain on sale of contingent payments	$0-100.0%	$889.1M	$0-100.0%	$127.9M
Milestone payment from gain on sale of oncology business	$0-100.0%	$200.0M	$0	$0
Interest income, net	$56.4M+17.3%	$48.1M+44.2%	$33.3M+160.6%	$12.8M
Other income, net	$2.0M-69.8%	$6.5M+7.1%	$6.1M-10.3%	$6.7M
Net (loss) income before taxes	-$413.8M-157.6%	$718.0M+303.9%	-$352.1M-51.9%	-$231.8M
Income tax (benefit) expense	-$1.0M-102.3%	$44.2M	$0	$0
Net (loss) income	-$412.8M-161.3%	$673.7M+291.4%	-$352.1M-51.9%	-$231.8M
Net income (loss) per share - basic (in usd per share)	-$7120.00-160.0%	$11860.00+287.4%	-$6330.00-49.6%	-$4230.00
Net income (loss) per share - diluted (in usd share)	-$7120.00-161.2%	$11640.00+283.9%	-$6330.00-49.6%	-$4230.00
Weighted-average number of common shares used in computing net income (loss) per share – basic (in shares)	$57972004000.00+2.1%	$56807415000.00+2.1%	$55651487000.00+1.6%	$54789435000.00
Weighted-average number of common shares used in computing net income (loss) per share – diluted (in shares)	$57972004000.00+0.1%	$57889255000.00+4.0%	$55651487000.00+1.6%	$54789435000.00
Product revenue, net

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 11 more years of annual history and full quarterly detail on Pro.

Upgrade to Pro →

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.